Overview

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Status:
TERMINATED
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
Phase:
PHASE1
Details
Lead Sponsor:
Atara Biotherapeutics